Lv3
260 积分 2025-01-16 加入
Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation
11小时前
已完结
Belantamab mafodotin, lenalidomide, and dexamethasone for intermediate-fit and frail patients with newly diagnosed myeloma
9天前
已关闭
Renal insufficiency in multiple myeloma: a systematic review and meta-analysis of all randomized trials from 2005–2019
9天前
已完结
Frailty measures in multiple myeloma: evaluating the impact on outcomes and quality-of-life in clinical trials and real-world practice
9天前
已完结
Direct Anti-Globulin Test and Clinical Diagnosis
9天前
已完结
TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy
10天前
已完结
Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study
10天前
已完结
603 | THE EFFICACY AND SAFETY OF ZANUBRUTINIB IN COMBINATION WITH R‐CHEMO IN THE FIRST‐LINE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MANTLE CELL LYMPHOMA
10天前
已完结
607 | EFFICACY AND SAFETY OF ZANUBRUTINIB COMBINED WITH BENDAMUSTINE AND RITUXIMAB AS FIRST‐LINE TREATMENT FOR MANTLE CELL LYMPHOMA
10天前
已完结
Warm autoimmune haemolytic anaemia: Clinical considerations
16天前
已完结
HYDRA: A Multi-Level Hierarchy-Driven Approach for Robust Anomaly Detection in Time Series
皖公网安备34019202002308
